The Delivery Platform Portfolio: Trade-Named, Patent-Pending Across the Full Stack

Atumnus Life Sciences holds the intellectual property estate beneath the Opticeutical category. The portfolio is patent-pending across multiple jurisdictions and is not publicly disclosed at the level of specific filings, sequences, or claim language while prosecution continues. What follows is the publicly stateable shape of the portfolio at a level appropriate for partners, journalists, and category observers.

Three layers, integrated

The portfolio operates at three layers. At the compound layer, a portfolio of trade-named peptide-class compositions covering seven therapeutic coverage areas. At the delivery layer, a portfolio of trade-named delivery platforms covering every consumer route of administration relevant to the category. At the carrier layer, a therapeutic salt carrier system — including the Opti-Salt™ carrier family — that addresses the bioavailability, stability, and dissolution requirements specific to short-chain peptide formulation.

The three layers are designed to be integrated. A specific peptide-class composition is delivered through a specific platform using a specific carrier chemistry. The IP architecture protects the integration as well as the components. This is the design choice that distinguishes the Atumnus portfolio from single-compound, single-route, single-formulation IP positions held by other companies operating adjacent to the category.

Seven coverage areas

The compound portfolio is organised across seven therapeutic coverage areas. Each area corresponds to an organ-system or functional domain that the bioregulator research lineage has characterised in depth and for which consumer-facing translation is appropriate under the Opticeutical Standard. The coverage areas are not individually disclosed at this stage of prosecution. The shape of the portfolio — distributed across multiple tissue-specific domains rather than concentrated in any single one — is the disclosure relevant to partners and observers.

The seven-area structure reflects the underlying biology. The bioregulator research lineage has consistently observed that short-chain regulatory peptides exhibit tissue-specific effects. The IP portfolio is structured to honour that tissue-specificity. A compound effective in one coverage area is not asserted to be effective across all seven, and the portfolio does not require any single compound to perform multiple unrelated functions. Specificity is the point.

Every consumer route of administration

The delivery platform portfolio covers every consumer route of administration that the category requires: oral, sublingual, mucosal, transdermal, microneedle, personalised, smart-connected, veterinary, and agricultural. Each route is supported by a trade-named platform engineered specifically for the chemistry and behaviour of peptide-class compounds at that route, with the formulation discipline that the Opticeutical Standard requires.

The depth of the delivery coverage matters because the category cannot exist if it is limited to a single delivery form. Different coverage areas require different routes. Different consumer use-cases require different forms. The portfolio is built to support the full surface of category expression, not a single product line within it.

“Most bioregulator intellectual property covers a single compound, a single route, or a single layer of the stack. A category requires more.”

The Opti-Salt™ carrier system

The therapeutic salt carrier layer addresses a specific formulation problem. Short-chain peptides, in their free-acid form, are moisture-sensitive, pH-sensitive, and prone to enzymatic degradation. Conventional pharmaceutical excipients can stabilise them in some applications but rarely with the dissolution profile and bioavailability characteristics that consumer products require.

The Opti-Salt™ carrier family is a system of therapeutic salt formulations engineered for peptide-class compound delivery in consumer products. The carrier chemistry is pharmaceutically defensible without invoking a new excipient class that would require de novo regulatory characterisation. The system is the bioavailability backbone of the delivery platform portfolio, supporting the bioavailability pillar of the Opticeutical Standard across multiple routes of administration.

How partners engage with the portfolio

Qualified manufacturing, formulation, and brand partners engage with the portfolio under license. Licensing arrangements are bilateral and tied to specific coverage areas, specific platforms, or specific carrier applications. Atumnus does not pursue universal licensing arrangements. The category exists by virtue of selectivity, and the licensing posture mirrors the selectivity of the standard.

Partner inquiries regarding licensing, data room access for qualified parties, or coverage-area-specific collaboration are routed through the partnerships channel. Public press inquiries regarding the portfolio architecture are routed through the media channel. Inquiries regarding the underlying scientific basis are routed to the institutional reference at endogenicpharmacology.com.

On what we have not disclosed

Specific filing numbers, priority dates, claim counts, sequence-level details, and compound chemistries are not publicly disclosed while patent prosecution continues. This is standard practice and is not negotiable. Qualified partners with executed mutual non-disclosure agreements may receive substantially more detailed treatment through the data room. The public posture is intentionally conservative on IP-specific detail and intentionally explicit on category posture, standard, and architecture. The reader should expect both to remain consistent throughout the prosecution period.